DEPAKOTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPAKOTE (DEPAKOTE).
Increases GABA levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
| Metabolism | Extensively metabolized in the liver via glucuronidation (UGT1A3, UGT2B7), beta-oxidation, and cytochrome P450 (CYP) pathways; minor CYP involvement (CYP2C9, CYP2C19, CYP2A6). |
| Excretion | Renal: <3% as unchanged drug; >95% as metabolites (glucuronide conjugates, oxidation products). Biliary/fecal: minor, <5%. |
| Half-life | Terminal: 9-16 hours (mean 12 h); extended with hepatic dysfunction, co-administered enzyme inhibitors, or in elderly. |
| Protein binding | 90-95% bound, primarily to albumin; concentration-dependent at therapeutic levels. |
| Volume of Distribution | 0.13-0.23 L/kg; distributes mainly in plasma and extracellular fluid; minimal CNS penetration. |
| Bioavailability | Oral: ~100% (immediate-release); extended-release formulations ~90% relative to IV. |
| Onset of Action | Oral: 1-4 hours for peak serum concentrations; clinical effect in 3-5 days for seizure control; weeks for mood stabilization. IV: immediate for seizure termination. |
| Duration of Action | Oral: 8-12 hours for steady-state; therapeutic effect persists with regular dosing. IV: seizure control duration 4-6 hours post-infusion. |
| Molecular Weight | 144.21 |
| Action Class | Sodium channel modulators (AED) |
| Brand Substitutes | Divox 1000mg Tablet, Divalin OD 1000mg Tablet, StayHappi Divalproex 1000mg Tablet, Dixval OD 1000mg Tablet, Proexsun 1000mg Tablet |
Initial dose 750 mg/day PO in divided doses; increase by 250-500 mg/day every 3-7 days; maintenance dose 1000-2000 mg/day PO divided BID or TID; maximum 60 mg/kg/day.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No dose adjustment required for renal impairment; dialyzable, post-hemodialysis supplementation may be needed. |
| Liver impairment | Contraindicated in severe hepatic impairment; in mild-to-moderate (Child-Pugh A/B), reduce dose and monitor liver function; avoid in Child-Pugh C. |
| Pediatric use | 10-15 mg/kg/day PO divided BID or TID; increase by 5-10 mg/kg/day weekly; maximum 60 mg/kg/day; monitor serum levels and side effects. |
| Geriatric use | Start at lower doses, 250-500 mg/day PO; titrate slowly; monitor for encephalopathy, thrombocytopenia, and tremor; reduce dose if renal function decreased. |
| 1st trimester | High risk of neural tube defects (1-2% incidence) and major congenital malformations including craniofacial defects, cardiac malformations. Avoid unless no alternative. |
| 2nd trimester | Continued risk of congenital malformations; may be used if benefits outweigh risks. Monitor for fetal growth restriction and maternal toxicity. |
| 3rd trimester | Risk of neonatal hemorrhage and hepatic toxicity; may be used if benefits outweigh risks. Neonatal withdrawal syndrome and hypoglycemia possible. |
Clinical note
Comprehensive clinical and safety monograph for DEPAKOTE (DEPAKOTE).
| Placental transfer | Extensive; crosses placenta readily, achieving fetal serum concentrations similar to maternal levels. Active transport via placental anion exchange. |
| Breastfeeding | Small amounts excreted in breast milk; infant serum levels are low. Generally considered compatible but monitor infant for drowsiness, poor feeding, and hepatotoxicity. AAP recommends caution. |
■ FDA Black Box Warning
Hepatotoxicity, especially in children under 2 years, patients with metabolic disorders, or those on multiple anticonvulsants; Fetal risk, including neural tube defects (spina bifida) and other congenital malformations; Pancreatitis, including fatal hemorrhagic cases.
| Serious Effects |
Hypersensitivity to valproic acid or derivativesHepatic disease or significant hepatic dysfunctionUrea cycle disorders (e.g., ornithine transcarbamylase deficiency)
| Precautions | Hepatotoxicity (monitor LFTs), pancreatitis (discontinue if symptoms), thrombocytopenia, hyperammonemic encephalopathy, teratogenicity, multiorgan hypersensitivity reactions, sedation, and weight gain. |
| Food/Dietary | Avoid alcohol. May be taken with food to reduce GI upset. Grapefruit juice has not been reported to significantly interact. No specific dietary restrictions required, but maintain consistent intake of sodium and fluids to avoid electrolyte imbalances. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - limited data suggest low risk, but caution advised. |
| Teratogenic Risk | First trimester: High risk of neural tube defects (spina bifida, anencephaly) with incidence ~1.5–2.9% for monotherapy; increased risk of orofacial clefts, cardiovascular defects, hypospadias. Second/third trimester: Risk of neurodevelopmental delay, autism spectrum disorder, reduced IQ; may cause fetal growth restriction, preterm birth. Peripartum: Neonatal hemorrhage, hepatic toxicity, hypoglycemia, withdrawal symptoms. |
| Fetal Monitoring | Preconception: folate 5 mg/day; ensure lowest effective dose. First trimester: high-resolution ultrasound for neural tube defects (NTD) at 16-18 weeks, fetal echocardiography at 18-22 weeks. Throughout: serial growth scans, amniocentesis for NTD if indicated. Maternal: liver function tests, CBC, coagulation profile, valproate serum concentrations (target lowest effective level). Newborn: monitoring for hemorrhage (vitamin K prophylaxis), hypoglycemia, withdrawal. |
| Fertility Effects | May cause reversible ovulatory dysfunction due to weight gain, insulin resistance, polycystic ovary syndrome (PCOS) in some women; reported increased risk of anovulation. No direct adverse effect on spermatogenesis reported. Valproate does not impair fertility after discontinuation. |
| Clinical Pearls | Valproate (Depakote) is a broad-spectrum antiepileptic and mood stabilizer. Monitor trough serum levels (therapeutic range 50-100 mcg/mL for epilepsy, 50-125 for bipolar). Check LFTs and CBC at baseline and periodically; valproate can cause hepatotoxicity and thrombocytopenia. Hyperammonemia may occur even with normal LFTs—consider if encephalopathic symptoms present. Pancreatitis is rare but serious; discontinue if suspected. Avoid in pregnancy due to neural tube defects; use effective contraception in women of childbearing potential. Dose adjustment needed in hepatic impairment. Co-administration with lamotrigine increases lamotrigine levels; reduce lamotrigine dose. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly as seizures or mood episodes may worsen. · Swallow tablets whole; do not crush or chew delayed-release or extended-release forms. · If you miss a dose, take it as soon as remembered unless near next dose; do not double. · Report any signs of liver problems: nausea, vomiting, abdominal pain, dark urine, jaundice. · Report easy bruising or bleeding (low platelets) or severe abdominal pain (pancreatitis). · Avoid alcohol; may increase sedation and worsen liver side effects. · Women of childbearing age must use effective contraception; discuss pregnancy plans with doctor. · May cause drowsiness or dizziness; avoid driving until you know how you react. · Regular blood tests are needed to monitor drug levels and organ function. · Do not take with other medications without consulting your doctor, especially aspirin, warfarin, or other seizure meds. |